Literature DB >> 11856078

The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review.

E V Loftus1, P Schoenfeld, W J Sandborn.   

Abstract

AIM: To quantify, through systematic review, the epidemiology and natural history of Crohn's disease in North America.
METHODS: The selected articles contained: (i) population-based samples of patients followed from the time of diagnosis; and (ii) objective diagnostic criteria for disease. Studies on the natural history of Crohn's disease also contained sufficient follow-up. DATA COLLECTION AND ANALYSIS: For prevalence studies, data on the incidence, prevalence, gender and age at diagnosis were extracted. For natural history studies, data on the disease activity, use of medications and surgery were extracted. MAIN
RESULTS: The prevalence of Crohn's disease in North America ranges from 26.0 to 198.5 cases per 100,000 persons. The incidence rates range from 3.1 to 14.6 cases per 100,000 person-years. Most patients have a chronic intermittent disease course, while 13% have an unremitting disease course and 10% have a prolonged remission. Less than half require corticosteroids at any point. During any given year, approximately 10% are treated with corticosteroids and 30% are treated with 5-aminosalicylates. Up to 57% of patients require at least one surgical resection.
CONCLUSIONS: Between 400,000 and 600,000 patients in North America have Crohn's disease, and the natural history is marked by frequent exacerbations requiring treatment with corticosteroids, 5-aminosalicylate products and surgery.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11856078     DOI: 10.1046/j.1365-2036.2002.01140.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  125 in total

1.  Incidence and prevalence of ulcerative colitis in Punjab, North India.

Authors:  A Sood; V Midha; N Sood; A S Bhatia; G Avasthi
Journal:  Gut       Date:  2003-11       Impact factor: 23.059

2.  Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease.

Authors:  W J Sandborn; E V Loftus
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

3.  New Data on the Use of Biologic Agents for Crohn's Disease and Ulcerative Colitis: Highlights from the 2009 CCFA Advances in IBD Meeting.

Authors:  Edward V Loftus
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-02

4.  Biologic Therapies for Crohn's Disease: Update from the 2009 ACG Meeting.

Authors:  David G Binion
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-01

Review 5.  Comparison of strictureplasty and endoscopic balloon dilatation for stricturing Crohn's disease--review of the literature.

Authors:  Andreas G Wibmer; Anton J Kroesen; Jörn Gröne; Heinz-Johannes Buhr; Joerg-Peter Ritz
Journal:  Int J Colorectal Dis       Date:  2010-07-14       Impact factor: 2.571

6.  Pseudosibship methods in the case-parents design.

Authors:  Zhaoxia Yu; Li Deng
Journal:  Stat Med       Date:  2011-09-23       Impact factor: 2.373

7.  Outcomes of computed tomography and magnetic resonance enterography in clinical practice of inflammatory bowel disease.

Authors:  Niraj S Patel; Suresh Pola; Ramya Muralimohan; G Y Zou; Cynthia Santillan; Derek Patel; Barrett G Levesque; William J Sandborn
Journal:  Dig Dis Sci       Date:  2013-12-10       Impact factor: 3.199

8.  Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan.

Authors:  Fumiaki Ueno; Toshiyuki Matsui; Takayuki Matsumoto; Katsuyoshi Matsuoka; Mamoru Watanabe; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2012-10-23       Impact factor: 7.527

Review 9.  Preoperative optimization of crohn disease.

Authors:  Amit Sharma; Bertram T Chinn
Journal:  Clin Colon Rectal Surg       Date:  2013-06

Review 10.  Colonic crohn disease.

Authors:  Traci L Hedrick; Charles M Friel
Journal:  Clin Colon Rectal Surg       Date:  2013-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.